Nuvalent/$NUVL

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Nuvalent

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Ticker

$NUVL

Sector

Health
Primary listing
NASDAQ

Employees

162
Headquarters
Cambridge, United States
Website
www.nuvalent.com

Nuvalent Metrics

BasicAdvanced
$5.2B
-
-$4.90
-
-

What the Analysts think about Nuvalent

Analyst ratings (Buy, Hold, Sell) for Nuvalent stock.

Bulls say / Bears say

Nuvalent's lead drug candidates, zidesamtinib and NVL-655, are progressing through Phase 2 trials, with pivotal data expected in 2025, potentially leading to regulatory approvals and market entry. (Investing.com)
Analysts project significant revenue growth for Nuvalent, estimating revenues of $205 million in 2026, growing to $4.5 billion by 2032, indicating substantial market potential. (Investing.com)
Nuvalent's focus on developing brain-penetrant tyrosine kinase inhibitors addresses a critical need in treating non-small cell lung cancer with brain metastases, potentially offering a competitive advantage. (Investing.com)
Nuvalent is currently operating at a loss, with an EBITDA of -$141.48 million and projected negative earnings per share for FY2025, indicating financial challenges common in clinical-stage biotech companies. (Investing.com)
The oncology market, particularly for non-small cell lung cancer treatments, is highly competitive, posing risks from established players and emerging therapies that could impact Nuvalent's market share. (Investing.com)
Nuvalent's recent secondary share offering of over 5.3 million shares at $56 each may lead to stock dilution, potentially affecting existing shareholders' value. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.

Nuvalent Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Nuvalent Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NUVL

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs